Hosted on MSN

FDA approves Edwards’ TAVR system for asymptomatic aortic stenosis patients

The US Food and Drug Administration (FDA) has approved Edwards Lifesciences' SAPIEN 3 transcatheter aortic valve replacement (TAVR) platform for the treatment of patients with asymptomatic severe ...
BioWorld

Edwards’ Early TAVR refutes surveillance recs for aortic stenosis

Don’t wait. Edwards Lifesciences Corp.’s additional insights from the Early TAVR trial showed a clear benefit for transcatheter aortic valve replacement (TAVR) in patients with asymptomatic aortic ...
Seeking Alpha

Edwards Lifesciences upgraded at JP Morgan on TAVR, TMTT strength

JP Morgan upgraded Edwards Lifesciences (EW) to overweight from neutral highlighting accelerating growth in its transcatheter aortic valve replacement (TAVR) division and strength in its transcatheter ...
Nasdaq

Edwards SAPIEN 3 TAVR Delivers Proven Long-term Benefits and Valve Performance, New Data Presented at TCT 2025

SAN FRANCISCO--(BUSINESS WIRE)-- Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The ...
Business Wire

Edwards TAVR Receives FDA Approval for Patients With Asymptomatic Severe Aortic Stenosis

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) announced today that the U.S. Food and Drug Administration (FDA) has approved its transcatheter aortic valve replacement (TAVR) therapy ...